Insulin Glargine (Lantus, Basaglar, Toujeo): Complete Clinical Guide

What Is Insulin Glargine and How Does It Work?

Insulin glargine is a recombinant human insulin analog modified at two positions to shift its isoelectric point toward physiologic pH. When injected subcutaneously, the acidic solution (pH 4.0) neutralizes and forms microprecipitates that dissolve slowly, releasing insulin into the bloodstream at a near-constant, peakless rate over approximately 24 hours for 100 U/mL formulations and up to 36 hours for the 300 U/mL Toujeo formulation. [1]

This peakless profile matters clinically. Traditional NPH insulin peaks 4-12 hours after injection, which drives nocturnal hypoglycemia; glargine largely eliminates that peak. A 2002 meta-analysis in Diabetes Care (N=2,304) confirmed that basal insulin glargine cut symptomatic nocturnal hypoglycemia by roughly 40% compared with NPH in patients with Type 2 diabetes. [2]

Mechanistically, glargine binds the insulin receptor and IGF-1 receptor, suppressing hepatic glucose output and stimulating peripheral glucose uptake in muscle and adipose tissue. The FDA-approved labeling for Lantus describes its action onset as approximately 2-4 hours after injection with no pronounced peak. [3]

Lantus vs. Basaglar vs. Toujeo: Key Differences

The three brands share one amino-acid backbone but are not interchangeable without dose adjustment in the case of Toujeo.

Lantus (insulin glargine-yfgn, Sanofi) launched in 2000 and remains the reference product. Each milliliter contains 100 units. It comes in a 10 mL vial and a SoloStar prefilled pen. [3]

Basaglar (insulin glargine-yfgn, Eli Lilly/Boehringer Ingelheim) received FDA approval in 2015 as a follow-on biological to Lantus, the first insulin product to use the FDA's 351(k) biosimilar pathway. Concentration is identical at 100 U/mL. The FDA states that Basaglar is not rated as interchangeable with Lantus under the current labeling, meaning a pharmacist cannot automatically substitute one for the other without prescriber authorization in most states, though clinical outcomes data show equivalent glycemic control. [4]

Toujeo (insulin glargine-yfgn 300 U/mL, Sanofi) delivers three times more insulin per milliliter. Because of the higher concentration and smaller injection volume, the subcutaneous depot is denser and dissolves even more slowly, extending duration to 36+ hours and further flattening the activity profile. [5] In the EDITION 1 trial (N=807, Type 2 diabetes on basal-bolus therapy), Toujeo produced equivalent HbA1c reduction to Lantus at 6 months while significantly cutting nocturnal hypoglycemia (relative risk reduction approximately 21%, P<0.05). [6]

Switching from Lantus or Basaglar to Toujeo is a unit-for-unit conversion initially, with an expected 10-18% higher total daily dose needed over time to match glycemic control, per the prescribing information. [5] Switching from Toujeo back to a 100 U/mL product typically requires a 20% dose reduction to prevent hypoglycemia.

Approved Indications and Age Restrictions

Lantus and Basaglar are FDA-approved for adults and pediatric patients age 6 and older with Type 1 diabetes, and for adults with Type 2 diabetes. [3][4] Toujeo carries a slightly broader pediatric label: in 2022 the FDA extended Toujeo approval to children age 6 and older for both Type 1 and Type 2 diabetes. [5]

Pediatric dosing requires particular care. The American Diabetes Association (ADA) 2024 Standards of Care state: "Basal insulin analogs (glargine, detemir, degludec) are preferred over NPH insulin in children and adolescents with Type 1 diabetes due to lower hypoglycemia risk." [7]

No insulin glargine product is approved for use during diabetic ketoacidosis. IV regular insulin remains the treatment of choice for DKA. [8]

Dosing and Titration Protocols

Starting doses depend on diabetes type and prior insulin exposure. For insulin-naive adults with Type 2 diabetes, the ADA 2024 Standards recommend initiating basal insulin at 10 units/day or 0.1-0.2 units/kg/day. [7]

Titration targets fasting plasma glucose between 80 and 130 mg/dL. A simple self-titration protocol studied in the TITRATE trial (N=289) used a once-weekly 2-unit increase when three consecutive fasting glucoses exceeded 130 mg/dL, achieving target in 63% of patients at 24 weeks without clinician-initiated dose changes. [9]

For Type 1 diabetes, basal insulin typically covers 40-50% of total daily insulin needs, with the remainder provided by prandial (rapid-acting) insulin at meals. The ratio may shift based on carbohydrate intake, activity level, and concurrent medications.

Injection technique affects results. Rotating sites across abdomen, thigh, and upper arm prevents lipohypertrophy, which slows and unpredictably alters absorption. The American Diabetes Association advises a minimum 1-cm distance between injection sites within the same region. [7]

HealthRX Basal Insulin Titration Framework (for clinical reference)

| Fasting Glucose (mg/dL) | Suggested Weekly Dose Adjustment | |---|---| | <80 (hypoglycemia) | Reduce by 10-20% or 2-4 units | | 80-130 (at target) | No change | | 131-160 | Increase by 2 units | | 161-180 | Increase by 4 units | | >180 | Increase by 6 units |

This framework aligns with the ADA 2024 "fasting glucose-guided titration" recommendations and the INSIGHT titration algorithm validated in the TITRATE trial. [7][9]

Hypoglycemia: Rates, Risk Factors, and Management

Hypoglycemia is the most clinically significant adverse effect of insulin glargine. The ORIGIN trial (N=12,537, median follow-up 6.2 years) reported a severe hypoglycemia rate of 1.00 event per 100 person-years in the glargine group, vs. 0.31 events per 100 person-years in the standard-care group. [10] Severe hypoglycemia (requiring third-party assistance) was rare but real.

Risk factors include skipped meals, unplanned exercise, alcohol intake, renal impairment (which slows insulin clearance), and dose errors. Patients with eGFR <30 mL/min/1.73m² should be monitored more frequently because glargine clearance decreases with declining kidney function. [3]

Nocturnal hypoglycemia is the primary concern with basal insulins. The EDITION program (four Phase III trials comparing Toujeo vs. Lantus) consistently found that Toujeo cut any nocturnal symptomatic hypoglycemia by 21-31% in various patient subgroups. [6]

Treatment of mild-to-moderate hypoglycemia follows the "15-15 rule": 15 grams of fast-acting carbohydrate, recheck in 15 minutes, repeat if glucose remains <70 mg/dL. Severe hypoglycemia requires glucagon (1 mg IM/SC for adults, 0.5 mg for children <25 kg) or 25 mL of 50% dextrose IV. [8]

Injection Site Reactions and Other Side Effects

Local reactions at the injection site affect a meaningful minority of users. Redness, swelling, and itching typically resolve within a few days to weeks. Lipohypertrophy (fat build-up from repeated injections in the same spot) can create variable absorption and erratic glucose readings; rotating sites resolves this in most cases. [3]

Systemic allergic reactions are rare but can include urticaria, angioedema, and anaphylaxis. Patients who experience generalized rash or difficulty breathing after an injection require immediate emergency evaluation. [3]

Weight gain is an expected pharmacologic effect of insulin therapy. The ORIGIN trial reported a mean weight gain of 1.6 kg in the glargine group over 6.2 years vs. a 0.5 kg loss in the standard-care group. [10] Combining glargine with a GLP-1 receptor agonist (for example, liraglutide or semaglutide) can partially offset this weight gain while improving HbA1c. The DUAL I trial (N=1,091) showed that IDegLira (a basal insulin/GLP-1 combination product, analogous in concept to iGlarLixi which combines glargine with lixisenatide) reduced HbA1c by 1.9% while producing a mean weight loss of 0.5 kg over 26 weeks. [11]

How Insulin Glargine Compares With Oral Agents

Many patients with Type 2 diabetes use insulin glargine alongside or after oral agents. Understanding where glargine fits in the treatment sequence requires knowing how it differs from the main oral options.

Metformin

Metformin remains the first-line oral agent for Type 2 diabetes per ADA 2024 and American Association of Clinical Endocrinology (AACE) guidelines. [7][12] It works primarily by suppressing hepatic glucose production (the same pathway glargine partially covers) and does not cause hypoglycemia as monotherapy. The UKPDS 34 trial (N=753, overweight patients) showed metformin reduced diabetes-related endpoints by 32% compared with diet alone at a median 10.7 years, with no associated weight gain. [13]

Glargine is typically added when metformin alone (or metformin plus one or two additional oral agents) no longer keeps HbA1c below the individualized target. The ADA recommends adding basal insulin when HbA1c remains above goal despite dual oral therapy, or when HbA1c is above 10% at diagnosis. [7]

Glipizide (Sulfonylurea)

Glipizide and other sulfonylureas stimulate pancreatic beta-cell insulin secretion. They effectively lower glucose but carry a meaningful hypoglycemia risk because they work independently of ambient glucose levels. In a head-to-head comparison (UKPDS 34 subset and subsequent trials), sulfonylureas produced similar HbA1c reductions to metformin initially but were associated with greater weight gain (approximately 2-3 kg) and higher rates of hypoglycemia. [13] When patients on a sulfonylurea require intensification, adding basal glargine is a common and guideline-supported approach, though the provider should consider reducing or stopping the sulfonylurea to lower hypoglycemia risk once insulin is initiated. [7]

Pioglitazone (Actos)

Pioglitazone is a thiazolidinedione that improves insulin sensitivity in peripheral tissues, reducing the amount of endogenous insulin needed to maintain glucose control. The PROactive trial (N=5,238) showed pioglitazone reduced the secondary composite cardiovascular endpoint (nonfatal MI, stroke, death) by 16% vs. placebo over 34.5 months. [14] However, pioglitazone causes fluid retention and can precipitate or worsen heart failure, which limits its use in patients who already need insulin (a population with higher cardiovascular risk). The FDA added a black box warning for heart failure on all thiazolidinedione labels. [15] When pioglitazone and insulin glargine are combined, patients should be monitored for edema and signs of cardiac decompensation.

Empagliflozin (Jardiance)

Empagliflozin is an SGLT-2 inhibitor that causes glycosuria, lowering blood glucose independent of insulin. The EMPA-REG OUTCOME trial (N=7,020, patients with established cardiovascular disease) showed empagliflozin reduced cardiovascular death by 38% and hospitalization for heart failure by 35% vs. placebo over a median 3.1 years. [16] Because of this cardiorenal benefit, ADA 2024 recommends empagliflozin (or another SGLT-2 inhibitor) in patients with Type 2 diabetes and established heart failure or chronic kidney disease, regardless of HbA1c level. [7]

Adding empagliflozin to insulin glargine therapy is an evidence-based combination. The EMPA-REG OUTCOME population included patients on insulin, and the cardiovascular benefit was maintained. When empagliflozin is added to an insulin regimen, the insulin dose often requires a 10-20% reduction to prevent hypoglycemia. [16] Providers should also counsel on euglycemic diabetic ketoacidosis (euDKA), a rare but serious risk when SGLT-2 inhibitors are used with insulin, particularly perioperatively. [17]

Cardiovascular Safety: The ORIGIN Trial

The ORIGIN trial (Outcome Reduction with an Initial Glargine Intervention, N=12,537) is the definitive long-term cardiovascular safety study for insulin glargine. Published in the New England Journal of Medicine in 2012, ORIGIN randomized patients with dysglycemia or early Type 2 diabetes to glargine titrated to a fasting glucose target of <95 mg/dL vs. standard care, following them for a median 6.2 years. [10]

The primary outcome (nonfatal MI, nonfatal stroke, or cardiovascular death) occurred in 2.94 events per 100 person-years in the glargine group vs. 2.85 per 100 person-years in standard care (hazard ratio 1.02 to 95% CI 0.94-1.11, P = 0.63 for superiority). Glargine was cardiovascularly neutral. [10] The NEJM editorial accompanying the publication noted: "The results should reassure clinicians that early insulin therapy does not increase cardiovascular risk in patients with dysglycemia."

Glargine also did not increase cancer incidence in ORIGIN, resolving earlier observational concerns about insulin analogs and IGF-1 receptor stimulation. [10]

Pharmacokinetics, Drug Interactions, and Special Populations

Glargine has no active metabolites relevant to dose adjustment. It is metabolized in the liver, muscle, and kidney by the same pathways as endogenous insulin. Several drug classes alter insulin requirements:

Beta-blockers can mask tachycardia (a key hypoglycemia symptom) and may modestly prolong recovery from hypoglycemia. [3] Corticosteroids substantially raise insulin requirements; patients starting prednisone typically need a 20-50% glargine dose increase, depending on prednisone dose and duration. Fluoroquinolone antibiotics have been associated with both hypoglycemia and hyperglycemia in case reports and FDA safety communications. [18]

Renal impairment increases hypoglycemia risk. A pharmacokinetic study published in Diabetes Care found that glargine exposure (AUC) increased by approximately 25% in patients with moderate renal impairment (eGFR 30-59 mL/min/1.73m²) compared with normal renal function. [19] Dose reductions of 20-30% are often needed as eGFR falls below 45 mL/min/1.73m².

Pregnancy requires close glucose monitoring. The ADA recommends targeting fasting glucose <95 mg/dL and 1-hour postprandial <140 mg/dL during pregnancy. [7] Human insulin (NPH and regular) is traditionally preferred because more long-term safety data exist; however, observational data and a 2020 Cochrane review (20 trials, N=1,864) found no significant differences in maternal or neonatal outcomes between insulin glargine and NPH during pregnancy. [20]

Storage, Handling, and Pen/Vial Specifics

Unopened Lantus and Basaglar vials and pens must be refrigerated at 36-46°F (2-8°C) and are stable until the printed expiration date. [3][4] Once in use, the 10 mL vial can be kept at room temperature (below 77°F) for up to 28 days; the SoloStar pen for up to 28 days unrefrigerated. [3]

Toujeo Max SoloStar and SoloStar pens in use can be stored at room temperature below 86°F for up to 42 days. [5] Do not freeze any insulin glargine product. Freezing destroys the protein structure and renders the insulin inactive without any visible change in appearance.

Never mix glargine in the same syringe as rapid-acting insulin or any other insulin. The acidic pH of glargine will precipitate other insulins and alter the pharmacokinetics of both. [3]

Cost, Insurance, and Biosimilar Access

List prices for insulin glargine products vary widely. As of 2024, Sanofi's list price for Lantus is approximately $325 per vial. Basaglar, launched at roughly 15% below Lantus's list price at introduction, offers meaningful savings for cash-pay patients. Sanofi launched an authorized generic Lantus at $99/vial in 2023 under the Valyou savings program. [3]

The Inflation Reduction Act (effective January 2023 for Medicare Part D enrollees) caps cost-sharing for insulin at $35/month per covered insulin product. [21] Patients with commercial insurance should verify formulary placement, as Basaglar holds preferred formulary status on many plans due to its lower negotiated price.

Patient assistance programs from Sanofi (Insulins Valyou Savings Program) and Eli Lilly (Lilly Cares Foundation) provide free or heavily discounted insulin to eligible low-income patients. [22]

Monitoring Parameters and HbA1c Targets

The ADA 2024 Standards set a general HbA1c target of <7.0% for most non-pregnant adults, with less stringent targets (<8.0%) acceptable for older adults with complex comorbidities or limited life expectancy, and more stringent targets (<6.5%) for younger patients with short disease duration who can achieve them without significant hypoglycemia. [7]

Self-monitored blood glucose (SMBG) frequency depends on insulin regimen. Patients on basal-only insulin should check fasting glucose daily at minimum to guide titration. The ADA also endorses continuous glucose monitoring (CGM) for any insulin-using patient; CGM reduces HbA1c by an additional mean 0.4-0.5% compared with SMBG alone in patients on basal insulin, based on a 2021 JAMA trial (N=175). [23]

Time-in-range (70-180 mg/dL) is an emerging metric with CGM. An expert consensus statement from the American Diabetes Association in Diabetes Care (2019) recommends a time-in-range target of >70% for most adults with diabetes. [24]